Everything below concerns c-Met. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| Typical supplied form | Lyophilized powder | Stored desiccated before use |
| Recommended storage | -20 °C | Protect from light and moisture |
| Common stock solvent | Dimethyl sulfoxide | Aqueous solubility may be limited |
| Purity method | Reverse-phase HPLC | Reports percent purity and impurities |
| Identity method | Mass spectrometry | Confirms molecular mass |
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
== Safety considerations == Inhalation of crystalline silica harms the lungs, causing silicosis. Amorphous silica is considered to have low toxicity, but prolonged inhalation causes lung changes. Diatomaceous earth is mainly amorphous silica but contains some crystalline silica, especially in the saltwater forms. In a 1978 study of workers, those exposed to natural diatomaceous earth for over five years had no significant lung changes while 40% of those exposed to the calcined form had developed pneumoconiosis. Today's standard diatomaceous earth formulations are safer to use, as they are predominantly made of amorphous silica and contain little or no crystalline silica. The crystalline silica content of diatomaceous earth is regulated in the United States by the Occupational Safety and Health Administration (OSHA). There are guidelines from the National Institute for Occupational Safety and Health that set maximum amounts allowable in the product (1%) and in the air near the breathing zone of workers, with a recommended exposure limit at 6 mg/m3 over an 8-hour workday. OSHA has set a permissible exposure limit for diatomaceous earth as 20 mppcf (80 mg/m3/%SiO2). At levels of 3,000 mg/m3, diatomaceous earth is immediately dangerous to life and health. In the 1930s, workers with long-term occupational exposure in the cristobalite diatomaceous earth industry who were exposed to high levels of airborne crystalline silica over decades were found to have an increased risk of silicosis.
=== Conservation === In Southeast Asia, the king cobra is threatened foremost by habitat destruction owing to deforestation and expansion of agricultural land. It is also threatened by wildlife smuggling, as well as by poaching, then sold as bushmeat or turned into snake leather, and for use in traditional Chinese medicine. The king cobra is listed in CITES Appendix II. It is protected in China and Vietnam. In India, it is placed under Schedule II of Wildlife Protection Act, 1972. Killing a king cobra is punished with imprisonment of up to six years. In the Philippines, king cobras (locally known as banakon) are included under the list of threatened species in the country. It is protected under the Wildlife Resources Conservation and Protection Act (Republic Act No. 9147), which criminalises the killing, trade, and consumption of threatened species with certain exceptions (like indigenous subsistence hunting or immediate threats to human life), with a maximum penalty of two years imprisonment and a fine of ₱20,000.
=== 1982–1994 === The company established its presence in the US in 1982 via a joint venture with Squibb Corporation and Canada in 1984. In 1985, the company introduced the first insulin pen device called Novopen. In 1989, Novo Industri (Novo Terapeutisk Laboratorium) and Nordisk Gentofte (Nordisk Insulinlaboratorium) merged to become Novo Nordisk, the world's largest producer of insulin with headquarters in Bagsværd, Greater Copenhagen. In 1991, Novo Nordisk Engineering (now NNE) demerged after working as in-house consultants at Novo for years, to provide standard engineering services (end-to-end engineering) to pharma manufacturing companies. In 1994, Novo's existing information technology units was spun out as NNIT. The company was converted into a wholly owned aktieselskab in 2004. In March 2015, NNIT was floated on the Nasdaq Nordic.
=== Thyroxine, iodine and apoptosis === Thyroxine and iodine stimulate the apoptosis of the cells of the larval gills, tail and fins in amphibian metamorphosis, and stimulate the evolution of their nervous system transforming the aquatic, vegetarian tadpole into the terrestrial, carnivorous frog. In fact, amphibian frog Xenopus laevis serves as an ideal model system for the study of the mechanisms of apoptosis.
Sources: en.wikipedia.org
=== In the Mediterranean === The first biological evidence for reduced environments in the Mediterranean Sea was the presence of Lucinidae and Vesicomyidae bivalve shells cored on the top of the Napoli mud volcano (33°43′52″N 24°40′52″E; "Napoli" is only a name of a seamount. It is located south of Crete), located at 1,900 m deep on the Mediterranean Ridge in the subduction zone of the African Plate. This was followed by the description of a new Lucinidae bivalve species, Lucinoma kazani, associated with bacterial endosymbionts. In the southeastern Mediterranean, communities of polychaetes and bivalves were also found associated with cold seeps and carbonates near Egypt and the Gaza Strip at depths of 500–800 m, but no living fauna was collected. The first in situ observations of extensive living chemosynthetic communities in the eastern Mediterranean Sea prompted cooperation between biologists, geochemists, and geologists. During submersible dives, communities comprising large fields of small bivalves (dead and alive), large siboglinid tube worms, isolated or forming dense aggregations, large sponges, and associated endemic fauna were observed in various cold seep habitats associated with carbonate crusts at 1,700–2,000 m depth. Two mud volcano fields were first explored, one along the Mediterranean Ridge, where most of them were partially (Napoli, Milano mud volcanoes) or totally (Urania, Maidstone mud volcanoes) affected by brines, and the other on the Anaximander mounds south of Turkey.
== Reception == White House Press Secretary Karoline Leavitt described the plaques as "eloquently written descriptions" that serve as a "testament to the Greatness of America". Critics and groups such as the National Trust for Historic Preservation have criticized the installation, alongside other 2025 renovations like the demolition of the East Wing for a planned state ballroom, as an attempt to politicize the historic fabric of the White House.
=== Viscosity === Semen viscosity can be estimated by gently aspirating the sample into a wide-bore plastic disposable pipette, allowing the semen to drop by gravity and observing the length of any thread. High viscosity can interfere with determination of sperm motility, sperm concentration and other analysis.
Sources: en.wikipedia.org
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.
Mass spectrometry is commonly used to confirm molecular mass, while reverse-phase HPLC assesses purity. Some laboratories also use nuclear magnetic resonance for structural verification. These methods are standard for research peptides.
Aqueous solubility can be limited and varies by batch and salt form. Dimethyl sulfoxide is often used for stock solutions. Supplier documentation or a solubility test can clarify behavior for a given lot.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.